Harrow Inc (HROW) - News Archive

In a move that could significantly impact the accessibility of ophthalmic treatments, Harrow (NASDAQ: HRRO) has recently introduced their Harrow Access for All (HAFA) initiative. This groundbreaking program is designed...

Harrow Reports Q1 2025 Financial Results Amid Ongoing Investor Engagement NASHVILLE, Tenn. Harrow Health, Inc. (NASDAQ: HROW), a prominent player in the North American eyecare pharmaceutical space, has announced its fin...

In a landmark legal victory, Harrow Health, Inc. (Nasdaq: HROW) proudly announced that its wholly owned subsidiary, ImprimisRx, LLC, has been awarded $34.9 million in a unanimous jury verdict against OSRX, Inc. The case...

Harrow Inc. (Nasdaq: HROW) Announces Participation in Upcoming Conferences NASHVILLE, Tenn. October 2023 Harrow Inc. a prominent eyecare pharmaceutical company based in North America, has announced its participation in...

Harrow Demonstrates Robust Growth and Strategic Expansion in Third Quarter 2024 Financial Report and Future Endeavors Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, has recently released...

Expanding Access and Affordability: Harrow s Innovative Initiative in Eyecare Pharmaceuticals In recent years, the rising cost of prescription medications has been a major concern among patients, healthcare providers, a...

Harrow Inc. Revives TRIESENCE: A Steady Step Forward in Ocular Treatments In a significant development for the ophthalmic pharmaceutical landscape, Harrow Inc. (Nasdaq: HROW), a prominent North American eyecare pharmace...

In a recent announcement, Harrow, a prominent North American eyecare pharmaceutical company, disclosed its plan to attend the highly anticipated 2024 American Society of Retina Specialists (ASRS) Annual Meeting. The eve...

Harrow Joins Apexus 340B Prime Vendor Program to Expand Access to IHEEZO and Other Essential Eyecare ProductsNASHVILLE, Tenn. - Harrow, a prominent eyecare pharmaceutical company in North America, has officially partner...

Combining the articles mentioned:Harrow Provides TRIESENCE Relaunch Update and Announces Investor Conference ParticipationNASHVILLE, Tenn. - Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company...

Harrow, a renowned North American eyecare pharmaceutical company, has recently unveiled encouraging results from their ESSENCE2 open-label extension (OLE) clinical study for VEVYE (cyclosporine ophthalmic solution) 0.1%...

Harrow to Present at Two Investor Conferences in MayNASHVILLE, Tenn. - Harrow (Nasdaq: HROW), a prominent eyecare pharmaceutical company in North America, recently made an exciting announcement regarding its participati...

In a recent announcement, Harrow, a renowned eyecare pharmaceutical company in North America, disclosed its financial results for the first quarter ended on March 31, 2024. This disclosure included the publication of th...

Analyzing Harrow s First Quarter 2024 Financial Results: Assessing the Impact on the Leading Eyecare Pharmaceutical CompanyHarrow, a prominent U.S. eyecare pharmaceutical company, recently revealed its financial results...